Article · 28 Jun 2025
Research articlePublished 2015
Cardiac Effects of Glucagon-Like Peptide 1 with Chitosan-Based Scaffold after Inducing Myocardial Infarction in Dogs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aims: Glucagon-like peptide 1 (GLP-1) is one of the new choices in the management of diabetes mellitus because of its glucose regulatory effects. GLP-1 receptors are expressed not only in islet cells, kidney, lung, brain, and gastrointestinal tract, but also in the heart. The cardiac effects of GLP-1 play a major role in the choice to use this treatment, considering the expression of GLP-1 receptors in heart. Degradation by dipeptidyl peptidase-IV (DPPIV) makes GLP-1’s half-life very short. In this study, the cardiac effects of GLP-1 with chitosan-based scaffold as well as the tissue changes after induction of myocardial infarction in canines were evaluated. Method: Twelve canines of a similar breed and weight were included in this study. They were categorized into three groups: A case group treated with GLP-1 based on a chitosan scaffold, a group given chitosan with normal saline, and a control group given normal saline alone. Every four weeks after induction of infarction, the troponin-I serum level, regional wall motion abnormality (RWMA), angiogenesis, and microscopic and macroscopic tissue changes were analyzed. Results: Angiogenesis and infarcted area thickness (which is inversely related to the subsequent risk of pseudoaneurysm development) were significantly higher in the case group compared with the other two groups (p value<0.05). Our case group recorded lower scores of RWMA compared with other canines (p value=0.02). Conclusion: This investigation revealed that the new compound (GLP-1+chitosan) not only lengthens the releasing duration of GLP-1 but also has cardioprotective effects after myocardial infarction.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cardiovascular Pharmacology: Open Access.
Article · 28 Jun 2025
Beta Blockers and Their Expanding Role in Cardiovascular Disease
Article · 28 Jun 2025
Emerging Role of PCSK9 Inhibitors in Lipid Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCardiovascular Pharmacology: Open Access
- SubjectPharmaceutical Sciences
- SubjectCardiology
- BylineArticles whose byline prints “Sam Zeraatian”
- BylineArticles whose byline prints “Abbas Salehiomran”
- BylineArticles whose byline prints “Ruhollah Mehdinavaz Aghdam”
- BylineArticles whose byline prints “Seyed Hossein Ahmadi Tafti”
- BylineArticles whose byline prints “Seyed Reza Ghiasi”
- BylineArticles whose byline prints “Nasim Kiaee”
- BylineArticles whose byline prints “Shahram Rabbani”
- BylineArticles whose byline prints “Ali Ghiasedin”
